News

23 Mar 2018

Statement in response to the EU Council ratifying the Brexit transition deal

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today respond...

Read more
13 Mar 2018

European Investment Bank report: “Financing the next wave of medical breakthroughs – What works and what needs fixing?”

EBE was proud to support the launch of the European Investment Bank's report "Access-to-finance conditions for Life Sciences R&D" at BioEurope Spring. This reports identifies a number of neces...

Read more
26 Feb 2018

EBE at Bio Europe Spring 2018 – “Funding gaps in the European Life Science Sector”

14 March 2018 from 9h00 - 10h00 CET at RAI Amsterdam Convention Center, Room E107, Europa plein, NL 1078 GZ Amsterdam, The Netherlands The European Investment Bank (EIB) and the European Commission...

Read more
15 Jan 2018

EBE Reflection Paper on Medicinal product incorporating a drug delivery device component: An Industry Perspective on the EU marketing application technical requirements, regulatory review process and post-approval device related change assessment

Within the European Biopharmaceutical Enterprises (EBE), a working group focused on EU specific topics relating to those integral combination products, which are regulated as medicinal products but wh...

Read more
19 Dec 2017

EFPIA-EBE White Paper: Expedited CMC Development- Accelerated Access for Medicines of Unmet Medical Need

Since 2012 there has been a focus on faster translation of scientific breakthroughs to new, high quality medicines meeting unmet medical need through a programme initially referred to as Medicines Ada...

Read more
15 Dec 2017

Incentives for Innovation. Incentivising Research in Areas of High Unmet Medical Need: Lilly’s Alzheimer’s Quest

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems....

Read more
12 Dec 2017

Presentations and Conference Report from the 6th EBE Annual Conference on ATMPs – 5 December 2017, London

UPDATE 12 February 2018: Conference Report now available here The remarkable opportunities that cell and gene therapies can offer, but also the seemingly increasing number of obstacles to their w...

Read more
08 Dec 2017

Incentives, IP and smaller companies: the story of Lysogene

How Lysogene contributes to improving health outcomes Founded in France in 2009, and employing 18 staff at the end of 2017, Lysogene specialises in gene therapy targeting rare, neurod...

Read more
05 Dec 2017

Escher Study Identifies Hurdles to ATMP Development in Europe

First results of a study into factors associated with successful development of Advanced Therapy Medicinal Products (ATMPs) were reported today by Utrecht University at European Biopharmaceuti...

Read more
01 Dec 2017

Incentives for Innovation: the story of Gilenya by Novartis

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcar...

Read more
1 2 3 4 8